Developer docs
API playgroundTry for free, no card

Search company profiles

BAMCO Africa

Full company profile

uuid003y8t7

Namestring
BAMCO Africa
Legal namestring
BAMCO AFRICA, INC
Websiteurl
bamcoafrica.com
Company typeenum
Private
Founded yearint
2023
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKigali, Rwanda
HQ citystring
Kigali
HQ countrystring
Rwanda
HQ regionstring
Africa
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical market access, regulatory affairs services, clinical trial management, medical education programs, healthcare access advisory
Industry1 code
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Other Management Consulting Services541618
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Healthcare Market Access Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Partnerships and Access Solutions
TypeProfessional Services
Description

BAMCO Africa generates revenue through collaborating with pharmaceutical and biotechnology companies to introduce and expand access to standard-of-care treatments in Sub-Saharan Africa. They facilitate partnerships with public and private payers to increase the availability of essential medicines, offering regulatory, commercial, and distribution support for a fee or revenue share arrangement.

bamcoafrica.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BAMCO Africa is a Business Development, Access, Medical, and Clinical Operations healthcare company that facilitates patient access to innovative therapies in Sub-Saharan Africa, with focus on oncology and cardio-metabolic diseases. The company provides strategic partnerships with pharmaceutical and biotechnology firms, supports regulatory approval and commercialization, drives access to medicines through payer partnerships, delivers medical education, and organizes clinical trial operations across the region.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Brenzavvy (bexagliflozin) 20mg launched in Rwanda within two years of FDA approval - demonstrating ability to accelerate access to innovative treatments in SSA
Product overview1 text field

BAMCO Africa is a Business Development, Access, Medical, and Clinical Operations (BAMCO) healthcare company focused on providing access to innovative therapies for patients in Sub-Saharan Africa. The company operates a portfolio of interconnected service offerings including Strategic Partnerships (collaborating with pharmaceutical and biotechnology companies), Access to Medicines (facility partnerships with payers), Regulatory & Commercial Support, Medical Education, and Clinical Trials. In June 2025, BAMCO launched its first branded pharmaceutical product, Brenzavvy® (bexagliflozin) 20mg, an oral Type 2 Diabetes medication developed in partnership with TheracosBio. The company prioritizes oncology and cardio-metabolic diseases and works closely with governments across select Sub-Saharan African countries.

Product and service6 records
1Brenzavvy (bexagliflozin) 20mg
CategoryPharmaceutical Product
Description

Bexagliflozin 20mg tablet; first product launched in Rwanda through partnership with TheracosBio for treatment of cardio-metabolic diseases in Sub-Saharan African patients.

2Strategic Partnerships
CategoryBusiness Development Services
Description

Business development service that forges strategic alliances between international pharmaceutical/biotech innovators and Sub-Saharan African healthcare systems to bring novel therapies to the region.

3Access to Medicines
CategoryMarket Access Services
Description

Service that works with payers and healthcare providers to enable patient access to innovative therapies, particularly in oncology and cardio-metabolic disease areas.

4Regulatory and Commercial Support
CategoryRegulatory and Commercial Services
Description

Service that supports regulatory approval pathways and commercialization strategies for pharmaceutical products entering Sub-Saharan African markets.

5Medical Education
CategoryMedical Communications and Education
Description

Educational programs that train healthcare professionals in Sub-Saharan Africa on oncology and cardio-metabolic disease management and novel therapies.

6Clinical Trial Operations
CategoryClinical Research Services
Description

Clinical research services that organize and manage clinical trials across Sub-Saharan Africa for sponsor pharmaceutical and biotechnology companies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-18
Description

BAMCO Africa partnered with TheracosBio to bring affordably priced diabetes medication (Brenzavvy/bexagliflozin) to Sub-Saharan Africa. This landmark collaboration aims to make affordable diabetes treatment accessible to millions of patients across the region, addressing significant barriers to diabetes management due to high costs and limited resources. The partnership launched Brenzavvy in Rwanda in June 2025, within two years of FDA approval.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BAMCO Africa

Healthcare Market Access Servicesbamcoafrica.com

BAMCO Africa firmographics

Firmographics
Name
BAMCO Africa
Legal name
BAMCO AFRICA, INC
Website
https://bamcoafrica.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

BAMCO Africa industry classification

Industry
Product category
Healthcare Market Access Services
NAICS
Other Management Consulting Services (541618)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Pharmaceutical market access
  • Regulatory affairs services
  • Clinical trial management
  • Medical education programs
  • Healthcare access advisory

Where BAMCO Africa is headquartered

Location

Headquarters

HQ city
Kigali
HQ country
Rwanda
HQ region
Africa

Offices3 records

Markets served

BAMCO Africa business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Strategic Partnerships and Access Solutions: BAMCO Africa generates revenue through collaborating with pharmaceutical and biotechnology companies to introduce and expand access to standard-of-care treatments in Sub-Saharan Africa. They facilitate partnerships with public and private payers to increase the availability of essential medicines, offering regulatory, commercial, and distribution support for a fee or revenue share arrangement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

BAMCO Africa product offering

Product offering

Core offering

BAMCO Africa is a Business Development, Access, Medical, and Clinical Operations healthcare company that facilitates patient access to innovative therapies in Sub-Saharan Africa, with focus on oncology and cardio-metabolic diseases. The company provides strategic partnerships with pharmaceutical and biotechnology firms, supports regulatory approval and commercialization, drives access to medicines through payer partnerships, delivers medical education, and organizes clinical trial operations across the region.

Product overview

BAMCO Africa is a Business Development, Access, Medical, and Clinical Operations (BAMCO) healthcare company focused on providing access to innovative therapies for patients in Sub-Saharan Africa. The company operates a portfolio of interconnected service offerings including Strategic Partnerships (collaborating with pharmaceutical and biotechnology companies), Access to Medicines (facility partnerships with payers), Regulatory & Commercial Support, Medical Education, and Clinical Trials. In June 2025, BAMCO launched its first branded pharmaceutical product, Brenzavvy® (bexagliflozin) 20mg, an oral Type 2 Diabetes medication developed in partnership with TheracosBio. The company prioritizes oncology and cardio-metabolic diseases and works closely with governments across select Sub-Saharan African countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Brenzavvy (bexagliflozin) 20mg Bexagliflozin 20mg tablet; first product launched in Rwanda through partnership with TheracosBio for treatment of cardio-metabolic diseases in Sub-Saharan African patients.
  • Strategic Partnerships Business development service that forges strategic alliances between international pharmaceutical/biotech innovators and Sub-Saharan African healthcare systems to bring novel therapies to the region.
  • Access to Medicines Service that works with payers and healthcare providers to enable patient access to innovative therapies, particularly in oncology and cardio-metabolic disease areas.
  • Regulatory and Commercial Support Service that supports regulatory approval pathways and commercialization strategies for pharmaceutical products entering Sub-Saharan African markets.
  • Medical Education Educational programs that train healthcare professionals in Sub-Saharan Africa on oncology and cardio-metabolic disease management and novel therapies.
  • Clinical Trial Operations Clinical research services that organize and manage clinical trials across Sub-Saharan Africa for sponsor pharmaceutical and biotechnology companies.

Quantifiable outcome

  • Brenzavvy (bexagliflozin) 20mg launched in Rwanda within two years of FDA approval - demonstrating ability to accelerate access to innovative treatments in SSA

Companies that use BAMCO Africa

Customer profile

Segments1 record

Ideal customer profiles2 records

BAMCO Africa technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BAMCO Africa partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • TheracosBiocoreStrategic or Co-development Partner · 18 October 2024BAMCO Africa partnered with TheracosBio to bring affordably priced diabetes medication (Brenzavvy/bexagliflozin) to Sub-Saharan Africa. This landmark collaboration aims to make affordable diabetes treatment accessible to millions of patients across the region, addressing significant barriers to diabetes management due to high costs and limited resources. The partnership launched Brenzavvy in Rwanda in June 2025, within two years of FDA approval.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

BAMCO Africa competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

BAMCO Africa social profiles

Digital presence

BAMCO Africa financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BAMCO Africa leadership team

Management profile

Number of profiles

Profiles9 records

BAMCO Africa subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

BAMCO Africa funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BAMCO Africa M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BAMCO Africa

What does BAMCO Africa do?

BAMCO Africa is a Business Development, Access, Medical, and Clinical Operations healthcare company that facilitates patient access to innovative therapies in Sub-Saharan Africa, with focus on oncology and cardio-metabolic diseases. The company provides strategic partnerships with pharmaceutical and biotechnology firms, supports regulatory approval and commercialization, drives access to medicines through payer partnerships, delivers medical education, and organizes clinical trial operations across the region.

Is BAMCO Africa a public or private company?

BAMCO Africa is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BAMCO Africa founded?

BAMCO Africa was founded in 2023. It employs 1 to 10 people.

Where is BAMCO Africa based?

BAMCO Africa is headquartered in Kigali, Rwanda, in the Africa region.

How does BAMCO Africa make money?

One revenue line is on record: strategic Partnerships and Access Solutions.

Does BAMCO Africa have an API?

No public API is recorded for BAMCO Africa.

What industry is BAMCO Africa in?

BAMCO Africa's product category is Healthcare Market Access Services. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541618 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales